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Abstract
Background: It has been suggested that polymorphisms in glutathione-S-transferases (GST) could
predispose to prostate cancer through a heritable deficiency in detoxification pathways for
environmental carcinogens. Yet, studies linking GST polymorphism and prostate cancer have so far
failed to unambiguously establish this relation in patients. A retrospective study on healthy,
unrelated subjects was conducted in order to estimate the population GST genotype frequencies in
the Slovak population of men and compare our results with already published data (GSEC project-
Genetic Susceptibility to Environmental Carcinogens). A further aim of the study was to evaluate
polymorphisms in GST also in patients with prostate cancer in order to compare the evaluated
proportions with those found in the control subjects.
Methods: We determined the GST genotypes in 228 healthy, unrelated subjects who attended
regular prostate cancer screening between May 2005 and June 2007 and in 129 histologically
verified prostate cancer patients. Analysis for the GST gene polymorphisms was performed by PCR
and PCR-RFLP.
Results: We found that the GST frequencies are not significantly different from those estimated in
a European multicentre study or from the results published by another group in Slovakia. Our
results suggest that Val/Val genotype of GSTP1 gene could modulate the risk of prostate cancer,
even if this association did not reach statistical significance. We did not observe significantly
different crude rates of the GSTM1 and GSTT1 null genotypes in the men diagnosed with prostate
cancer and those in the control group.
Conclusion: Understanding the contribution of GST gene polymorphisms and their interactions
with other relevant factors may improve screening diagnostic assays for prostate cancer. We
therefore discuss issues of study feasibility, study design, and statistical power, which should be
taken into account in planning further trials.
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Prostate cancer is the most common cancer among men in
industrialized countries with the main risk factor being
the age of over 50. Prostate cancer is uncommon in men
younger than 45, but becomes more common with
increasing age. The average age at the time of diagnosis is
65 [1-4]. Since early detection increases the chance of suc-
cessful treatment, the prostate-specific antigen (PSA) test
and the digital rectal examination should be offered to
men annually beginning at age 50. Men with high risk
should begin testing at age 45. The only well-established
risk factors for prostate cancer are age, ethnicity, geogra-
phy and family history of prostate cancer. However,
research in the past few years has shown that genetic, soci-
oeconomic and environmental factors, particularly diet
and lifestyle, likely have an effect as well. It is assumed
that increased exposure to procarcinogens and carcino-
gens contained in tobacco smoke, debris, fermented food,
polluted water, air etc., is implicated in multistage car-
cinogenesis. Therefore, the assessment of the hazard of
prostate cancer coming from the pollution of the environ-
ment is of increasing importance. Moreover, the differ-
ences in the effectiveness of detoxification/activation of
carcinogens may help us understand why one man may
be at a higher risk than another [3].
Glutathione-S-transferase (GST) are phase II enzymes
which are responsible for catalyzing the biotransforma-
tion of a variety of electrophilic compounds, and have
therefore a central role in the detoxification of activated
metabolites of procarcinogens produced by phase I reac-
tions [5]. The GSTM1, GSTT1 and GSTP1 members of the
multigene family are candidate cancer-predisposing
genes. The relation of polymorphisms in these genes to
chemical carcinogenesis has been extensively studied in
various populations. Several population-based studies
have reported prevalence ranging from 47% to 58% for
the GSTM1 deletion genotype and from 13% to 25% for
the GSTT1-null genotype among white Europeans [1,6].
For GSTP1, the prevalence rates of Ile/Val heterozygosity
and Val/Val homozygosity were found to be between 38%
to 45.7% and 7% to 13% respectively [7].
GST deficiencies may increase the risk of somatic muta-
tion, which subsequently leads to tumor formation [6].
The absence of GSTM1 activity is caused by the inherit-
ance of two null alleles (alleles that have a deletion of the
GSTM1 gene). Similarly, individuals with no GSTT1 activ-
ity also have inherited null alleles of the GSTT1 gene. A
single nucleotide polymorphism in the GSTP1 gene
causes the substitution of isoleucine for valine at amino
acid codon 105 (Ile105Val), which substantially dimin-
ishes GSTP1 enzyme activity and lessens the effective
capacity for detoxification [8,9]. However, the published
data about the association of GST polymorphism and sus-
ceptibility to prostate cancer are controversial. Some stud-
ies suggest that the GSTM1, GSTT1 and GSTP1
polymorphisms are associated with prostate cancer sus-
ceptibility [10,11], whereas other studies report no associ-
ation [12,13].
The aim of this study was twofold: 1) to estimate the prev-
alence of the GSTM1, GSTT1 and GSTP1 gene polymor-
phisms in the Slovak population of men and compare
those results with the respective data published by other
groups (GSEC project – Genetic Susceptibility to Environ-
mental Carcinogens); and 2) to evaluate the frequencies
of the GSTT1 and GSTM1 null genotypes and polymor-
phisms in GSTP1 also in the patients with prostate cancer
in order to compare the evaluated proportions with those
found in the controls.
Methods
Case description
The present study was performed under the approval of
the Ethical Boards of Jessenius School of Medicine,
Comenius University and the informed written consent
was obtained from all individuals prior to their inclusion
in the study.
Blood samples from 228 subjects (median age of 63, IQR
56–70 years) were obtained from healthy, unrelated sub-
jects living in the north-western part of Slovakia, who
were invited to attend the Department of Urology for reg-
ular prostate cancer screening between May 2005 and
June 2007. The second part of the study was designed as a
case-control study (approximately two controls per one
case). The criteria for selecting patients were based on a
clinical proforma, covering medical, pathological and his-
topathological records. A total of 129 prostate cancer
patients (median age of 70, IQR 63–74 years) who were
histologically verified as having prostate cancer were
invited to participate in the project. Patients who had a
first-degree relative (brother or father) with a confirmed
diagnosis of prostate cancer were excluded in order to
avoid familial prostate cancer cases. The samples were
used for estimating GST gene frequencies.
Both patients and controls were interviewed regarding
age, smoking habits, possible chemical exposure, previous
and/or current prostate diseases, and incidence of cancer
and chronic diseases. The individuals were grouped in
never-smokers and ever-smokers. The studied population
is described in Table 1.
Chemicals
Proteinase K was obtained from AppliChem (DE). All the
primers, chemicals used for PCR and restriction enzyme,
were purchased from Eppendorf (USA). All other chemi-Page 2 of 8
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Co. (USA).
Genotyping
Peripheral venous blood was collected in 10 ml
heparinized tubes and the specimens were immediately
stored at -20°C for genotyping. From both, cases and con-
trols, genomic DNA was isolated from peripheral leuko-
cytes by proteinase K digestion, phenol/chloroform
extraction and ethanol precipitation, dissolved in TE
buffer (pH 7.5) and stored at -20°C until genotype analy-
sis.
A multiplex polymerase chain reaction (PCR) method was
used to detect either the presence or absence of GSTM1
and GSTT1 genes in the genomic DNA samples simultane-
ously in the same tube; β-globin gene was co-amplified
and used as an internal control [14]. This technique does
not distinguish between heterozygote and homozygote
GSTM1- and GSTT1-positive genotypes, but it does con-
clusively identify the null genotype [15]. Genomic DNA
(100 ng) was amplified in a total volume of 25 μl reaction
mixture containing 25 pmol of each GST primers
(GSTM1: forward 5'-GAA CTC CCT GAA AAG CTA AAG
C-3' and reverse 5'-GTT GGG CTC AAA TAT ACG GTG G-
3', GenBank accession no. NM_146421; GSTT1: forward
5'-TTC CTT ACT GGT CCT CAC ATC TC-3' and reverse 5'-
TCA CCG GAT CAT GGC CAG CA-3', GenBank accession
no. NM_000853); 25 pmol β-globin gene primers (for-
ward 5'-CAA CTT CAT CCA CGT TCA CC-3' and reverse 5'-
GAA GAG CCA AGG ACA GGT AC-3'); 200 μmol/l deox-
ynucleoside triphosphates; 1 U of Taq polymerase in 10 ×
PCR buffer composed of 16.6 mmol/l (NH4)2SO4 and
20.0 mmol/l MgCl2, pH 8.8. After initial denaturation for
3 min at 94°C, 39 cycles were performed for 1 min at
94°C (denaturation), for 1 min at 60°C (annealing) and
for 1 min at 72°C (extension), followed by a final step for
5 min at 72°C. The GSTM1 (215-bp), GSTT1 (480-bp)
and β-globin (268-bp) amplified products were visualized
by electrophoresis on ethidium-bromide-stained 3% aga-
rose gel (Fig. 1). For deletions of GSTM1 and GST1 no
amplified products can be observed, whereas the β-globin
specific fragment confirms the presence of amplifiable
DNA in the reaction mixture.
The GSTP1 Ile105Val substitution was detected using the
PCR-RFLP approach as the substitution by guanine intro-
duced restriction site that can be recognized by an endo-
nuclease Alw26I. PCR reactions were performed in a total
volume of 25 μl of solution containing 10 × PCR buffer
(16.6 mmol/l (NH4)2SO4, 20.0 mmol/l MgCl2, pH 8.8,
1.2 μl DMSO, 1.2 μl DTT), 200 μmol/l deoxynucleoside
triphosphates, 1 U of Taq DNA polymerase, 100 ng of
genomic DNA and 25 pmol of GSTP1 primers (forward 5'-
GTA GTT TGC CCA AGG TCA AG-3' and reverse 5'-AGC
CAC CTG AGG GGT AAG-3', GenBank accession no.
NM_000852). The reaction started for 3 min at 94°C, fol-
lowed by 5 cycles of PCR (cycle 1: 94°C for 15 s, 64°C for
30 s, and 72°C for 1 min) during which the annealing
temperature decreased by 1°C for each cycle. This step was
Table 1: General characteristic of the control and prostate cancer patient groups
Control group
Number (%) of subjects
Prostate cancer patients
Number (%) of subjects
No. 228 129
Smoking status
Smokers 51 (22%) 35 (27%)
Non-smokers 177 (78%) 94 (73%)
PSA (ng/ml, means ± SD) 2,73 ± 6,78 30,46 ± 77,89***
*** p < 0.001
Detection of polymerase chain reaction (PCR) amplification of GSTT1 (480 bp fragm nt), β-globin (268-bp fr gment) and GSTM1 (215-bp fragment) genesFigure 
Detection of polymerase chain reaction (PCR) ampli-
fication of GSTT1 (480 bp fragment), β-globin (268-bp 
fragment) and GSTM1 (215-bp fragment) genes. 
Absence of the PCR product indicates the null genotype. 
Ethidium bromide-stained electrophoresed representative 
PCR products samples: 100 bp ladder (lane L); absence of 
null genotypes (lanes 3, 4, 9); GSTT1-null allele (lanes 2, 5) 
and GSTM1-null allele (lanes 1, 2, 5, 6, 7, 8, 10, 11).Page 3 of 8
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annealing (for 30 s at 59°C), and extension (for 1 min at
72°C). A final polymerization step (for 5 min at 72°C)
was carried out to complete the elongation process and
yield a 442-bp fragment. A negative control (PCR without
template) was included in each set of PCR reactions. Each
PCR product (10 μl) was digested for 4 hours with the
restriction enzyme Alw26I (5 U) and electrophoresed on
ethidium-bromide-stained 1.5% agarose gel. The presence
of the Ile/Ile allele was detected by 329-, and 113-bp frag-
ments, whereas the Val/Val allele was confirmed by 216-,
and 113-bp fragments. The heterozygote Ile/Val allele was
characterized by fragments consisting of 329, 216, and
113 bp (Fig. 2) [7].
Statistical analysis
Age is presented as median and interquartile range (IQR)
because the data showed departures from normality
(according to Shapiro-Wilk's test). The χ2 method was
used to test frequencies of genotypes/allele in prostate
cancer patients and controls. The strength of the nominal
association in the contingency tables is reflected by
Cramér's (V) coefficient of contingency. The odds ratios
(OR), estimates of the relative risk, with 95% confidence
intervals (CI) were computed to assess strengths of associ-
ation of the genotypes with prostate cancer. All p values
cited are two-sided alternatives; differences resulting in a
p value of less or equal to 0.05 were declared statistically
significant [16]. The Hardy Weinberg equilibrium was
tested for the genotype proportions in the control group,
as a measure for quality control.
Results
Since previous reports suggested that there are no differ-
ences in GSTM1, GSTT1 and GSTP1 allele frequencies in
relation to age and sex [17], we conducted a retrospective
study on a selected population of men in order to examine
whether the gene frequencies were consistent with
research findings across Europe. Statistical analysis of data
collected from a survey of community sample in the
north-western part of Slovakia showed that our estimates
were not significantly different from either those found in
the Caucasian population of Garte and co-workers [1]
(Table 2) or those found previously by a research group in
Slovakia [1] (Table 3).
Among our control group, genotype frequencies did not
deviate significantly from the Hardy-Weinberg equilib-
rium [p = 0.72 (GSTP1), p = 0.8 (GSTT1) and p = 0.43
(GSTM1)].
Because the published data about the association of GST
polymorphism and susceptibility to prostate cancer are
not conclusive, and because it was suggested that the inci-
dence of prostate cancer varies with geography, the second
purpose of the study was to analyze the strength of these
associations in our selected population. Calculated chi-
square for equality of mean column scores and Cramér's
V yielded 0.506 and 0.023, respectively, which did not
account for significant differences in the GST frequencies
between healthy subjects and those diagnosed with pros-
tate cancer. The absence of any association between null
genotypes or polymorphism in GST and prostate cancer
was confirmed also by analyzing case-control groups.
Table 4 shows the distribution of the GST genotypes
among controls and prostate cancer patients. The patients
did not have significantly different frequencies in geno-
types and alleles in comparison to controls.
In addition, we have found no clear association between
smoking habits and prostate cancer, and between smok-
ing habits and single or combined genotypes in relation to
prostate cancer. Neither did the comprehensive score, a
pooled value indicating the presence of at least one vari-
ant allele, show a significantly reduced or unchanged risk
of prostate cancer (data not shown).
Discussion and evaluation
To assess possible association between GST gene poly-
morphisms and occurrence of prostate cancer in Slovakia,
we had to infer from population estimates acquired in the
first part of the study on a sample of 228 consecutive men
who scheduled appointments in the Department of Urol-
ogy.
It is known that the allele frequencies of metabolic genes
are not equally distributed throughout the human popu-
lation but follow diverse ethnic and/or geographic-spe-
cific patterns. Our results on GSTM1- and GSTT1-null
frequencies, 57% and 19.7%, respectively, did not differ
significantly either from the values obtained previously by
a Slovakian group of researchers (51.2% and 18%, respec-
tively) or from those published by other authors [1]. The
prevalence rate of Ile/Val heterozygosity and Val/Val
Cleavage of 442 bp PCR products of GSTP1 gene by the Alw26I r striction endonucleaseFigure 2
Cleavage of 442 bp PCR products of GSTP1 gene by 
the Alw26I restriction endonuclease. Ethidium bromide-
stained electrophoresed representative PCR-RFLP products 
samples: 100 bp ladder (lane L), Ile/Ile allele (lanes 2, 3, 5, 6); 
Ile/Val allele (lanes 1, 7, 8, 9) and Val/Val allele (lane 4).Page 4 of 8
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Table 2: Distribution of GSTP1, GSTT1 and GSTM1 genotypes in our control group and in Caucasian population (GSEC project-Genetic 
Susceptibility to Environmental Carcinogens) published by Garte and co-workers [1].
Polymorphism Our control group
Number (%) of subjects
Caucasians-GSEC
Number (%) of subjects
95% CI for proportion difference Cramér's V p-value
GSTP1
No. 228 1137
Ile/Ile 110 (48.2) 498 (43.8) -0.03 to 0.12 0.033 0.22
Ile/Val+Val/Val 118 (51.8) 561 (49.3) -0.05 to 0.09 0.018 0.51
GSTT1
No. 228 5577
positive 183 (80.3) 4774 (80.2)
null 45 (19.7) 1103 (19.8) -0.05 to 0.06 0.005 0.99
GSTM1
No. 228 10514
positive 98 (43.0) 4931 (46.9)
null 130 (57.0) 5583 (53.1) -0.03 to 0.10 0.011 0.24
Table 3: Distribution of GSTT1 and GSTM1 genotypes in our control group and in Slovak population (GSEC project-Genetic 
Susceptibility to Environmental Carcinogens) published by Garte and co-workers [1].
Polymorphism Our control group
Number (%) of subjects
Slovak population-GSEC
Number (%) of subjects
95% CI for proportion difference Cramér's V p-value
GSTT1
No. 228 332
positive 183 (80.3) 272 (82.0)
null 45 (19.7) 60 (18.0) -0.05 to 0.09 0.021 0.62
GSTM1
No. 228 332
positive 98 (43.0) 162 (48.8)
null 130 (57.0) 170 (51.2) -0.03 to 0.14 -0.057 0.18
Journal of Experimental & Clinical Cancer Research 2009, 28:32 http://www.jeccr.com/content/28/1/32homozygosity was 51.8% in our control subjects. This fre-
quency is also similar to the frequencies found in other
studies that analyzed GSTP1 polymorphism [18-20].
Some studies have reported a relationship between GST
variants and risk of prostate cancer [9,10,12,13,21]. Inves-
tigation of the GSTP1 gene did not reveal any significant
association between heterozygous GSTP1 genotype (Ile/
Val) and prostate cancer. However, our results suggest that
Val/Val genotype of GSTP1 gene could modulate the risk
of prostate cancer, even if this association did not reach
statistical significance. It should be kept in mind that the
inability to reject the null hypothesis could be due to low
power of the test because of a relatively small sample size.
Therefore, the lack of significance does not necessarily
mean equality of the distributions. It is plausible that pol-
ymorphism at the GSTP1 locus can play an important role
in the susceptibility to different types of cancer. Associa-
tion of the GSTP1 Val allele with cancer could be expected
since the conversion of the amino acid at codon 105 from
isoleucine to valine substantially lowers activity of the
altered enzyme. It has been predicted from molecular
modelling that the amino acid at this site lies in a hydro-
phobic binding site for electrophile substrates and thus
affects the substrate binding [22]. On the other hand,
there are also studies which did not prove any independ-
ent effect of this type of polymorphism on the susceptibil-
ity for prostate cancer [23-25].
In the present study, we did not observe significantly dif-
ferent crude rates of the GSTM1 and GSTT1 null genotypes
in the men diagnosed with prostate cancer and those in
the control group. Our data and the data published by
other research groups suggest that differences in the GST
frequencies between prostate cancer patients and the con-
trol group are relatively small, which therefore makes it
difficult to separate the groups from each other based on
statistical data analysis. Once again, the high variability in
the groups could mask statistical differences due to low
power. The easiest way to improve precision is to increase
the number of subjects and patients in the experimental
design. However, this may not be applicable to all
Table 4: Distribution of GSTP1, GSTT1 and GSTM1 genotypes in controls and patients with prostate cancer.
Polymorphism Controls
Number (%) of subjects
Cases
Number (%) of subjects
95% CI for proportion 
difference
Cramér's V OR (95% CI) p-value
GSTP1
No. 228 129
Ile/Ile 110 (48.2) 56 (43.4) 1.0
Ile/Val+Val/Val 118 (51.8) 73 (56.6) -0.15 to 0,06 0.047 0.72 (0.45 to 1.13) 0.38
Val/Val 5 (2.2) 6 (4.7) -0,08 to 0,01 0.068 2.17 (0.54 to 9.18) 0.22
GSTT1
No. 228 129
positive 183 (80.3) 105 (81.4) 1.0
null 45 (19.7) 24 (18.6) -0.08 to 0.09 -0.014 0.93 (0.51 to 1.66) 0.80
GSTM1
No. 228 129
positive 98 (43.0) 60 (46.5) 1.0
null 130 (57.0) 69 (53.5) -0,07 to 0,14 0.034 0.87 (0.55 to 1.37) 0.52Page 6 of 8
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poorer availability of resources, lower population, which
compromises the number of subjects eligible for investi-
gation. In order to achieve a power of at least 80%, we
have to identify other explanatory variables and the con-
trol for them, and/or apply meta-analysis in order to
increase sample size.
Recent studies on GST polymorphism have also evaluated
the combined effect of GSTM1 and GSTT1 genotypes, but
most of them failed to show any significant association
between the joint deficiency of these genes and prostate
cancer risk [24,26]; to our knowledge, only one study has
reported a significant increase prevalence of prostate can-
cer among carriers of both GSTM1 and GSTT1 null geno-
types [27]. Some studies, which combined data from
other genotypes, have shown that the concurrent lack of
GSTM1/GSTT1 and GSTP1 genes posed a significantly
increased risk of prostate cancer [20,28,29]. However,
these studies have not been confirmed by other authors
[23]. One of the reasons for such discrepancy in the find-
ings might lie in the difficulty of analyzing the impact of
the modified GST activity on detoxification of known car-
cinogens. GST has overlapping substrate specificities;
therefore, deficiency of a single GST isoenzyme may be
compensated by other isoforms. Another important factor
is the differential expression of genes for GST in different
cells.
The variation in published prostate cancer prevalence
rates can be attributed partly to methodological differ-
ences in survey design, including age distribution of the
population surveyed. It is also known that the incidence
of prostate cancer is underestimated, maybe due to poor
compliance of elderly with screening recommendations.
Thus, regular follow-ups are difficult to achieve and, as a
consequence, many men never know they have prostate
cancer. It has been reported that the calculated prevalence
of prostate cancer at death (i.e. histological evidence) for
a 60-year-old man is 32%, whereas but the prevalence in
living men (clinically-defined disease) is approximately
4% [30].
In contrast to the possible role of GST in environmental
carcinogenesis, it has been suggested that GST genotypes
conferring lower enzyme activity may be of advantage for
the patients who are undergoing chemotherapeutic treat-
ment for neoplastic disease because reduced detoxifica-
tion potentially enhances effectiveness of cytotoxic drugs
[31]. Although somewhat speculative, the GST polymor-
phisms might be a protective factor during the period of
chemotherapy, as the carriers of GST null genotypes might
better respond to the treatment. At present, it is difficult to
confidently evaluate the GST polymorphisms impact on
prostate cancer patients. Apparently, it would be far too
simplistic to attribute a complex problem such as prostate
cancer to any single cause. Although it is methodologi-
cally difficult to identify and separate all the factors that
make it difficult to identify individual changes, it is never-
theless possible to conduct a carefully designed interna-
tional and/or multicentric study, or of combining results
of several independent studies on the topic.
Conclusion
Our results suggest a possible association between the
GSTP1 Val/Val genotype and the occurrence of prostate
cancer. However, broad confidence intervals indicate a
naturally high variability in GST polymorphisms in the
population, which has given less weight to the observed
differences in GSTP1 Val/Val genotype frequencies
between the patients and the control subjects. Even if it
was shown that our study was not designed and powered
to detect single gene effects, as well as gene-environment
interactions, we cannot exclude that inter-individual dif-
ferences in GST enzyme activity mediated by polymorphic
genes, and reflected in insufficient detoxification of envi-
ronmental mutagens and carcinogens, may be involved in
the pathway, ultimately leading to tumor formation.
Because understanding of the contribution of GST gene
polymorphisms and their interactions with other relevant
factors may improve screening diagnostic assays for pros-
tate cancer, as well as clinical management of the patients,
further studies are needed to validate observed associa-
tions and to identify the causal sequence for prostate can-
cer from GST gene polymorphisms, providing it exists.
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